Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 7/20 | 0.68 |
| ▸ | CA12 | O43570 | 6/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.68 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.68 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.68 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.68 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.68 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26313592 | 0.88 | ALDH1A1 (0.58) | CA9CA12SMN1; SMN2CA2RAB9A | |
| SCHEMBL1421294 | 0.88 | SMN1; SMN2 (0.68) | SMN1; SMN2RAB9AALDH1A1TSHRMAPT | |
| SCHEMBL18767163 | 0.87 | ALDH1A1 (0.52) | CA9CA12SMN1; SMN2CA2RAB9A | |
| SCHEMBL6671420 | 0.86 | CYP2C19 (0.56) | CA9CA12SMN1; SMN2CA2RAB9A | |
| SCHEMBL11348726 | 0.85 | CA9 (0.52) | CA9CA12SMN1; SMN2CA2RAB9A | |
| SCHEMBL12613176 | 0.84 | ALDH1A1 (0.53) | CA9CA12SMN1; SMN2CA2RAB9A | |
| SCHEMBL18767224 | 0.84 | MAPT (0.55) | CA9CA12SMN1; SMN2CA2RAB9A | |
| Probenecid SCHEMBL3663 | 0.81 | CA9 (1.00) | CA9CA12SMN1; SMN2CA2RAB9A | |
| Probenecid SCHEMBL1034640 | 0.81 | CA9 (1.00) | CA9CA12SMN1; SMN2CA2RAB9A | |
| SCHEMBL8241614 | 0.80 | ALDH1A1 (0.55) | SMN1; SMN2CA2ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2023-08-17 | — | — | US | disclosed |
| WO-2017066742-A1 | BACE-2 INHIBITORY COMPOUNDS AND RELATED METHODS OF USE | JORTAN PHARMACEUTICALS INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| CN-102976980-B | Probenecid purification method | CHEMICAL TECHNOLOGY ACADEMY OF SHANDONG PROVINCE | 2014-06-25 | — | — | CN | disclosed |
| CN-103860559-A | Application of m-dipropylsulfamylbenzoic acid in veterinary drugs | QINGDAO BOITE BIOPHARM CO LTD | 2014-06-18 | — | — | CN | disclosed |
| CN-103860559-A | Application of m-dipropylsulfamylbenzoic acid in veterinary drugs | QINGDAO BOITE BIOPHARM CO LTD | 2014-06-18 | — | — | CN | disclosed |
| CN-102976980-A | Probenecid purification method | CHEMICAL TECHNOLOGY ACADEMY OF SHANDONG PROVINCE | 2013-03-20 | — | — | CN | disclosed |
| EP-1047670-A1 | AMINOSULPHONYLBENZAMIDE DERIVATIVES AS MODULATORS OF THE ACTIVITY OF NEURONAL CALCIUM CHANNELS | ELI LILLY AND COMPANY LIMITED (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036398-A1 | AMINOSULPHONYLBENZAMIDE DERIVATIVES AS MODULATORS OF THE ACTIVITY OF NEURONAL CALCIUM CHANNELS | ELI LILLY AND COMPANY LIMITED (GB) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | NLRP3, PYCARD, NLRP1 | CA9 2197/4885CA12 3513/4885SMN1; SMN2 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.